Extrawell Pharmaceutical Holdings Limited provided unaudited consolidated earnings guidance for the year ended 31 March 2023. For the year, Group expects to record a loss of about HKD 190 million as compared to a profit for the year ended 31 March 2022, which was primarily attributable to a non-cash item, resulted from a loss of about HKD 165 million arising from the fair value change of the Group's investments in convertible bonds, while a gain of about HKD 169 million due to the fair value change of the same non-cash item was incurred last year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.04 HKD | +33.33% | +25.00% | +17.65% |
2023 | Extrawell Pharmaceutical Swings to Fiscal H1 Loss on Fair Value Losses | MT |
2023 | Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+17.65% | 12.25M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- 858 Stock
- News Extrawell Pharmaceutical Holdings Limited
- Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023